UAE – Roche Diagnostics Middle East FZCO (RDME) and Burjeel Holdings have teamed up to leverage cutting-edge technology in digitizing and innovating laboratory processes.
Through the Digital Lab Incubation Partners umbrella, Roche and Burjeel Holdings will work closely not only to generate structured reports but also to use cases and whitepapers.
The duo will capture valuable knowledge and insights acquired from the digital initiatives, in line with concerted efforts to ensure early detection, accurate diagnoses, and timely treatment of diseases.
The Memorandum of Understanding (MoU) was signed by John Sunil, Chief Executive Officer of Burjeel Holdings, and Guido Sander, Roche Diagnostics Middle East FZCO General Manager.
In a press release, Guido Sander, General Manager at Roche Diagnostics Middle East FZCO, said: “This MoU reaffirms our commitment to providing advanced solutions that empower healthcare professionals and amplify the patient experience.”
By integrating cutting-edge technology into laboratory operations, Roche Diagnostics Middle East FZCO aims to accelerate the diagnostic process, ensuring more precise and timely interventions.
This collaboration aligns seamlessly with Roche’s mission to create a healthier future through innovation.
The companies will combine their expertise and technical support to develop innovative digital solutions across the entire healthcare spectrum.
“We embark on an inspiring journey with Burjeel Holdings, fuelled by the shared vision of transforming healthcare through digital diagnostics,” stated Guido Sander.
This partnership between Roche and Burjeel Holdings signifies a resolute commitment to elevating healthcare standards in the Middle Eastern region through innovation and collaboration.
The partnership between both companies is driven by their shared commitment to improving the patient experience and outcomes by providing accurate, reliable, and efficient services.
Commenting on this strategic partnership with Roche Diagnostics, Mr. John Sunil, CEO at Burjeel Holdings, underscored: “Through the integration of digital diagnostics, we aim to enhance the patient journey.”
Mr. John Sunil reiterated that Burjeel Holdings is committed to delivering faster and exceedingly accurate diagnoses and tailored treatment plans in alignment with the group’s commitment to excellence and innovation in healthcare.
Following the signing of the declaration, both organizations are looking forward to leveraging their collective strengths to bring about positive transformations in the healthcare landscape.
By joining forces with Roche, Burjeel Holdings aims to accelerate the development of precision medicine for improved early diagnosis and model personalized treatment pathways.
This collaboration stands as a testament to Burjeel Holdings’ dedication to offering the most advanced diagnostic solutions.
For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.
